Document is current

Article History

Received: 23 March 2026

Accepted: 1 August 2026

First Online: 19 August 2026

Declarations

Ethics approval and consent to participate: The study was conducted according to protocol 1483CESC approved by our local Ethics Committee, in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was collected for each participant.

Consent for publication: Patients provided consent for publication of anonymized data.

Conflicts of interest: O.V. declares advisory board honoraria and speaker fees from Gilead, Fresenius Kabi, Biogen, Eli Lilly, UCB, AbbVie, MSD, and BMS outside the submitted work. M.R. reports advisory board honoraria, consultancy fees and/or speaker fees from GSK, ItalFarmaco, Theramex, Janssen-Cilag, UCB, outside the submitted work. G. A. has received advisory board honoraria, consultancy fees and/or speaker fees from Theramex, UCB, Lilly, Galapagos, Fresenius Kabi, Amgen, BMS, Abiogen and Pfizer. D.G. declares advisory board honoraria, consultancy fees, and/or speaker fees from Accord Health Care, Abiogen, Amgen, Eli Lilly, Mereo, Neopharmed-Gentili, and UCB outside the submitted work. F.A. has received advisory board honoraria, consultancy fees and/or speaker fees from Boehringer Ingelheim, UCB Pharma, outside the submitted work.